Background
Chronic opioid use among people with HIV (PWH) remains an ongoing public health crisis. The interaction between opioids and HIV may exacerbate HIV-associated immune dysregulation and chronic inflammation, increasing the risk of both AIDS-related and non-AIDS-related morbidity and mortality. Treatment for opioid use disorder (OUD) includes opioid agonists such as buprenorphine or methadone, commonly referred to as treatment-as-usual (TAU), and the long-acting opioid antagonist extended-release naltrexone (XR-NTX).
Methods
Here we investigated if OUD treatment regimens impact immune regulation in PWH by analyzing clinical samples from participants in the open-label randomized CTN-067 CHOICES trial. All participants underwent ART initiation or optimization at enrollment, and treatment for four-to-six months with TAU (n=6) or XR-NTX (n=9). Blood samples were analyzed 6-month post-treatment initiation (when most participants had undetectable HIV plasma viral load) and included plasma-based cytokine analysis and peripheral blood mononuclear cell (PBMC) transcriptomic and epigenetic analysis using bulk RNA-seq and single-cell RNA/ATAC sequencing.
Results
Plasma cytokine milieu from TAU-treated individuals showed significantly higher levels of the pro-inflammatory cytokines IL-6 and IL-1β, with trends toward elevated IL-18, MIP-1α, TNF-α, and TGF-β3. Functional enrichment analysis between treatment cohorts revealed downregulation of inflammatory response pathways (TNF-α -signaling via NF-κB, Interferon-α and -g responses, IL6 JAK/STAT3 signaling, apoptosis) in participants treated with XR-NTX as compared to TAU. At the single-cell level, downregulation of these pathways was observed in several innate (monocytes) and adaptive (T and B cells) immune subsets, with reduced expression of NF-κB and interferon-related pathways. Chromatin accessibility in monocytes revealed closed NF-κB transcription factor binding sites in XR-NTX-treated participants, suggesting epigenetic remodeling consistent with reduced inflammation.
Conclusions
Taken together, these findings indicate that XR-NTX treatment attenuates the inflammatory cytokine milieu and signatures, contributing to the amelioration of immune function in PWH with OUD receiving ART. This highlights XR-NTX as a promising therapeutic strategy to reduce chronic inflammation and improve disease management in PWH with OUD.